Literature DB >> 18795934

Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization.

A Kedzierska1, M Kapińska-Mrowiecka, M Czubak-Macugowska, K Wójcik, J Kedzierska.   

Abstract

BACKGROUND: Staphylococcus aureus colonization is accepted to be an important triggering factor in patients with atopic dermatitis (AD) and antibiotic resistance has been recognized to be a serious problem as a consequence and for the management of AD treatment.
OBJECTIVES: To investigate the antibiotic resistance pattern of S. aureus strains isolated from patients with AD with apparent (lesional and nonlesional skin areas) and recurrent skin colonization and strains obtained from healthy nasal carriers.
METHODS: Eighty-seven patients (age 23+/-11.5 years) with mild to severe AD (SCORAD 46.9+/-16.6), 21 patients (age 19.8+/-6.7 years) before antistaphylococcal treatment and 177 healthy nasal carriers (age 27.5+/-8.4 years) were microbiologically assessed for carriage of S. aureus. Colonization of lesional and nonlesional skin areas was quantified by counting the number of colony forming units on the skin surface (log(10) CFU cm(-2)). Antimicrobial susceptibility and resistance phenotypes of 179 S. aureus strains were assessed with the agar disc-diffusion method.
RESULTS: Staphylococcus aureus was isolated from 87% of lesional and 44% of nonlesional skin samples from patients with AD. The colonization density of S. aureus was markedly higher in lesional than in nonlesional skin (P<0.001), and was positively correlated with AD severity (P<0.001) and total serum IgE (P<0.05). Patients with AD had a significantly higher prevalence of chloramphenicol-resistant S. aureus than nasal carriers (P<0.01). Similar rates of resistance were expressed to tetracycline, erythromycin, mupirocin, clindamycin and penicillin. Nearly 35% of S. aureus strains from the lesional skin demonstrated different antimicrobial sensitivity pattern compared with strains from nonlesional skin of the same patients with AD. The trend of increasing resistance to chloramphenicol, erythromycin and fusidic acid was observed among S. aureus strains recovered from patients after approximately 75 days of antibiotic treatment. Methicillin-resistant S. aureus isolates were cultured from two patients, one during exacerbation and the other after subsequent bacterial recolonization.
CONCLUSIONS: Discrepancies in antibiotic sensitivity pattern were observed among S. aureus strains colonizing different sites of AD skin (lesional and nonlesional areas), and also in AD patients with prior antibiotic treatment. Therefore, clinicians should consider repeat microbial susceptibility testing on different body sites of patients with AD when clinically indicated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795934     DOI: 10.1111/j.1365-2133.2008.08817.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure.

Authors:  Scott A Gerber; Ryan J Cummings; Jennifer L Judge; Margaret L Barlow; Julee Nanduri; Doug E Milano Johnson; James Palis; Alice P Pentland; Edith M Lord; Julie L Ryan
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

Review 2.  Ionizing radiation: the good, the bad, and the ugly.

Authors:  Julie L Ryan
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

3.  Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis.

Authors:  Mercedes E Gonzalez; Julie V Schaffer; Seth J Orlow; Zhan Gao; Huilin Li; Alexander V Alekseyenko; Martin J Blaser
Journal:  J Am Acad Dermatol       Date:  2016-09       Impact factor: 11.527

Review 4.  The role of antiseptic agents in atopic dermatitis.

Authors:  Melissa Lee; Hugo Van Bever
Journal:  Asia Pac Allergy       Date:  2014-10-29

5.  Change in Antimicrobial Susceptibility of Skin-Colonizing Staphylococcus aureus in Korean Patients with Atopic Dermatitis during Ten-Year Period.

Authors:  Jung-Min Park; Ju-Hyun Jo; Hyunju Jin; Hyun-Chang Ko; Moon-Bum Kim; Jung-Min Kim; Do-Won Kim; Ho-Sun Jang; Byung-Soo Kim
Journal:  Ann Dermatol       Date:  2016-07-26       Impact factor: 1.444

6.  Decolonization of Staphylococcus aureus in patients with atopic dermatitis: a reason for increasing resistance to antibiotics?

Authors:  Izabela Błażewicz; Maciej Jaśkiewicz; Marta Bauer; Lidia Piechowicz; Roman J Nowicki; Wojciech Kamysz; Wioletta Barańska-Rybak
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

7.  Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from patients with atopic dermatitis.

Authors:  Izabela Błażewicz; Maciej Jaśkiewicz; Lidia Piechowicz; Damian Neubauer; Roman J Nowicki; Wojciech Kamysz; Wioletta Barańska-Rybak
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

8.  Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients.

Authors:  Sofie Marie Edslev; Maja-Lisa Clausen; Tove Agner; Marc Stegger; Paal Skytt Andersen
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

9.  Determination of nasal carriage and skin colonization, antimicrobial susceptibility and genetic relatedness of Staphylococcus aureus isolated from patients with atopic dermatitis in Szczecin, Poland.

Authors:  Helena Masiuk; Aleksandra Wcisłek; Joanna Jursa-Kulesza
Journal:  BMC Infect Dis       Date:  2021-07-23       Impact factor: 3.090

10.  Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis.

Authors:  Caitriona Ryan; Richard E Shaw; Clay J Cockerell; Shari Hand; Fred E Ghali
Journal:  Pediatr Dermatol       Date:  2013 May-Jun       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.